Groowe Groowe BETA

US Stock Market News

Stay on top of the US stock market with real-time breaking news and market-moving stories. Our platform continuously aggregates updates from trusted financial news sources, giving traders and investors a fast overview of events that may impact stock prices.

Whether you're tracking specific companies or scanning the broader market, the news feed helps you quickly identify important developments as they happen.

Create an account to access the live news feed. Access is free while the platform is in beta. Visitors without an account can still browse the latest headlines with a 15-minute delay.

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

INVESTOR DEADLINE: Gartner, Inc. (IT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

prnewswire.com
IT

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Vital Farms, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - VITL

accessnewswire.com
VITL

Incyte annonce de nouvelles données positives de dernière minute portant sur 54 semaines concernant le povorcitinib dans le traitement de l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD)

businesswire.com
INCY

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

accessnewswire.com
ATRA

Europe 155mm Artillery Shells Market is Projected to Reach USD 870 Million by 2032 Amid Rising Defense Preparedness, Reports Vyansa Intelligence

prnewswire.com
ESLT GD

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages ODDITY Tech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ODD

globenewswire.com
ODD

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages ODDITY Tech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ODD

globenewswire.com
ODD

Incyte maakt nieuwe positieve, recent bekendgemaakte gegevens over een periode van 54 weken bekend voor povorcitinib bij hidradenitis suppurativa tijdens de jaarlijkse bijeenkomst van de American Academy of Dermatology (AAD) in 2026

businesswire.com
INCY

Incyte präsentiert neue positive 54-Wochen-Daten zu Povorcitinib bei Hidradenitis suppurativa auf der Jahrestagung 2026 der American Academy of Dermatology (AAD)

businesswire.com
INCY

Incyte annuncia gli ultimi nuovi dati positivi ottenuti in 54 settimane su povorcitinib nell'idrosadenite suppurativa al Meeting annuale 2026 della American Academy of Dermatology (AAD)

businesswire.com
INCY
View all news →